HER2-Positive Breast Carcinomas with Co-amplification or Gain of Chromosome 17 Centromere Locus: Report of Three Cases and an Impact on HER2 Testing
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Recently we experienced three cases of human epidermal growth factor receptor 2 (HER2)-amplified invasive breast carcinomas associated with co-amplification or gain of chromosome 17 centromere (CEP17) in silver-enhanced in situ hybridization (SISH) analysis. These cases revealed 2+ or 3+ staining for HER2 immunohistochemistry and >6 HER2 copies per cell on SISH analyses. However, the calculated HER2/CEP17 ratios were low (<2.2) and did not fit within the HER2-positive category. We interpreted those cases as HER2-positive tumors based on the number of HER2 copies per cell. There is a potential for misinterpretation of SISH analysis in cases showing increased CEP17 copy number, based on the criterion used for HER2 positivity (HER2 copies >6 per cell vs HER2/CEP17 ratio>2.2). We recommend reporting raw SISH or fluorescence in situ hybridization data, including number of cells counted, average numbers of HER2 and CEP17 signals, and the calculated HER2/CEP17 ratio to prevent underreporting of HER2 amplification.
Abstract
Recently we experienced three cases of human epidermal growth factor receptor 2 (HER2)-amplified invasive breast carcinomas associated with co-amplification or gain of chromosome 17 centromere (CEP17) in silver-enhanced in situ hybridization (SISH) analysis. These cases revealed 2+ or 3+ staining for HER2 immunohistochemistry and >6 HER2 copies per cell on SISH analyses. However, the calculated HER2/CEP17 ratios were low (<2.2) and did not fit within the HER2-positive category. We interpreted those cases as HER2-positive tumors based on the number of HER2 copies per cell. There is a potential for misinterpretation of SISH analysis in cases showing increased CEP17 copy number, based on the criterion used for HER2 positivity (HER2 copies >6 per cell vs HER2/CEP17 ratio>2.2). We recommend reporting raw SISH or fluorescence in situ hybridization data, including number of cells counted, average numbers of HER2 and CEP17 signals, and the calculated HER2/CEP17 ratio to prevent underreporting of HER2 amplification.
참고문헌 (15)
- Slamon DJ, "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2", N Engl J Med, 344, pp.783~792 (2001)
- Ross JS, "The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine", Oncologist, 14, pp.320~368 (2009)
- Harris L, "American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer", J Clin Oncol, 25, pp.5287~5312 (2007)
- Wolff AC, "American Society of Clinical Oncology", College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, 2007, pp.25, 118~145
- 배영경, "유방암에서 HER2 유전자 검사를 위한 자동화 은제자리부합법 검사의 유용성: 형광제자리부합법과 면역조직화학염색과의 비교", The Korean Journal of Pathology, 44(1), pp.28~34 (2010), 대한병리학회
- De P, "Human epidermal growth factor receptor 2 testing: where are we", J Clin Oncol, 28, pp.4289~4292 (2010)
- Baehner FL, "Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories", J Clin Oncol, 28, pp.4300~4306 (2010)
- Dal Lago L, "Correction for chromosome-17 is critical for the determination of true Her-2", neu gene amplification status in breast cancer, 2006, pp.5, 2572~2579
- Barberis M, "Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis", Am J Clin Pathol, 129, pp.563~570 (2008)
- Vranic S, "Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17", Cancer, 117, pp.48~53 (2011)
- Marchiò C, "Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis", J Pathol, 219, pp.16~24 (2009)
- Ross JS, "Human epidermal growth factor receptor 2 testing in 2010: does chromosome 17 centromere copy number make any difference", J Clin Oncol, 28, pp.4293~4295 (2010)
- Perez EA, "HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial", J Clin Oncol, 28, pp.4307~4315 (2010)
- Viale G, "Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer", J Pathol, 219, pp.1~2 (2009)
- Varga Z, "Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer", Breast Cancer Res Treat (2011)